The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.95
Bid: 2.90
Ask: 3.00
Change: -0.17 (-5.57%)
Spread: 0.10 (3.448%)
Open: 3.05
High: 2.88
Low: 2.88
Prev. Close: 3.05
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Ediston signs 10-year lease with Marks & Spencer

Wed, 01st Mar 2023 20:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Ediston Property Investment Co PLC - Edinburgh-based real estate investment company - Completes a 10-year lease agreement on a newly created 21,000 square feet unit with Marks & Spencer Group PLC at Plas Coch Retail Park, Wrexham. Adds that M&S will pay a market rent 27% ahead of the independent valuer's estimated rental value. Does not disclose further financial details. "Securing a tenant of M&S's calibre is transformational for our asset and underscores the strength of the location and its attractiveness to national tenants. It also illustrates the preference of many retailers to choose out-of-town retail warehouse parks ahead of the high street and shopping centres as their favoured trading destinations," Investment Manager Calum Bruce comments.

----------

RTW Venture Fund Ltd - New York-based investor in life sciences, biopharmaceutical, and medical technology companies - Co-leads a USD200 million series A round in Cargo Therapeutics LCC. Says that Cargo plans to use the proceeds for a phase 2 clinical development program and its pipeline of next-generation CAR T-cell programs and technologies. Co-leads a USD45 Million series B-1 round in China-based pharmaceutical company Oricell Therapeutics Co Ltd. Says that the company plans to use the proceeds to support its core product clinical development in the US.

----------

Upland Resources Ltd - Malaysia-focused upstream oil and gas company - Says its joint venture partner in Sarawak Upland Big Oil Sdn Bhd conducted geological fieldwork as part of the works for the Block SK334 onshore Sarawak joint technical study. Says that the preliminary findings were promising. "Preliminary findings from the geological field work study have been positive, Upland notes within Block SK334 a number of areas of specific interest with analogous geological configuration and reservoir/trap/seal combinations as Brunei's nearby Belait formation which is host to a number of proven oil and gas discoveries and oilfields," Chief Executive Bolhassan Di comments.

----------

Contango Holdings PLC - natural resource development company with operations in Africa - Completes the construction of a small-scale coke battery at the Lubu Coal Project in Zimbabwe. Says that it has produced around 4 tonnes of coke, from a sample of washed coking coal from Lubu. "The completion of the pilot coke plant will now enable us to generate larger coke production for testing, something required to enable us to conclude discussions under our memorandum of understanding and, as required, provide additional samples to other parties who have expressed interest in coke produced from Lubu," CEO Carl Esprey comments.

----------

Alkemy Capital Investments PLC - London-based company focused on acquisitions in the mining and technology metals sectors - Notes the completion of the acquisition of Britishvolt Tees Valley Lithium, a planned GBP3.8 billion Lithium-ion Gigafactory in Northern England by Australian Lithium-ion battery company Recharge. Explains that Recharge and its subsidiary Tees Valley Lithium Ltd signed an agreement to negotiate and finalise a definitive offtake agreement to supply tolled low-carbon lithium hydroxide into Recharge's qualified supply chain. Says that the Britishvolt project will be the UK's first Gigafactory and create a strategic economic and security asset which will play a critical role in the UK's industrial and net zero strategies.

----------

Standard Chartered PLC - London-based, Asia-focused lender - Fully redeems its USD1.00 billion fixed rate resetting perpetual subordinated contingent convertible securities. Says that the securities will be cancelled. Plans to make an application to The Stock Exchange of Hong Kong Ltd for the withdrawal of the listing of the securities, following the redemption.

----------

Canadian Overseas Petroleum Ltd - Wyoming, US-focused oil and gas company - Says its operating affiliate, COPL America, received a covenant waiver from its senior lender. Records production of 1,080 barrels of oil a day in January and 1,200 bbl per day in February, and estimates that production is currently at 1,400 bbl per day. Explains that it experienced several "severe winter storms" at its Wyoming operations from late December to late February. "This has been a difficult winter in Wyoming and western North America in general. The weather we have experienced has been well above historical averages. The interruption in our production operations has been difficult for all of us," CEO & President Arthur Millholland comments.

----------

ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Incoporates Inaphaea BioLabs Ltd as a new wholly owned subsidiary of the company and the cornerstone of ValiRx's translational contract research organisation. Says Inaphaea will be headquartered in the its laboratory in MediCity in Nottingham and will offer a wide range of pre-clinical and drug discovery testing services to academic, biotech and pharmaceutical researchers. "After a great deal of hard work by the entire ValiRx team, I am pleased to share this news about the formation of Inaphaea; the first step of our longer term ambition to create the unique tCRO service offering for early stage drug development. Over the next few weeks, we intend to transfer our own projects into the Inaphaea lab to continue their progress," CEO Suzy Dilly comments.

----------

By Abby Amoakuh, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
26 Mar 2019 10:22

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.Shares a

Read more
21 Mar 2019 09:53

ValiRx Notes Encouraging Performance Of VAL201 In Cancer Trial

LONDON (Alliance News) - ValiRx PLC on Thursday said an interim inspection of its VAL201 early phase cancer trial shows the drug is performing as predicted.Shares in ValiRx were up 13% at a

Read more
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more
9 Jan 2019 14:57

ValiRx gives NHS Long Term Plan its seal of approval

(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.

Read more
9 Jan 2019 11:25

ValiRx Backs New Long-Term UK Government Plan For NHS

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Wednesday said it endorses the UK government's new NHS long-term plan."The government's recently announced ten-year a

Read more
18 Dec 2018 15:53

VAL401 results accepted for journal publication, says ValiRx

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.

Read more
10 Dec 2018 11:07

ValiRx releases positive data from recent VAL201 testing

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Monday that independent analysis of VAL201 data showed a "statistically significant" dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.

Read more
10 Dec 2018 10:59

WINNERS & LOSERS SUMMARY: Just Group Jumps 23% On Regulatory Decision

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------NMC up The

Read more
10 Dec 2018 09:06

ValiRx Reports Positive VAL201 Effect On Patients With Prostate Cancer

LONDON (Alliance News) - ValiRx PLC on Monday said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer.The up

Read more
17 Oct 2018 08:36

ValiRx enters finals stages of clinical trials on VAL201

(Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.

Read more
25 Sep 2018 13:23

ValiRx Half Year Loss Widens On Expenses And Share Option Charge

LONDON (Alliance News) - Life science company ValiRx PLC on Tuesday reported a widened loss in the first half of 2018 due to expenses and a sizeable share option charge.The company's to

Read more
6 Sep 2018 11:38

ValiRx Says Clinical Study For Lung Cancer Drug VAL401 Is Approved

LONDON (Alliance News) - Clinical stage biotechnology company ValiRx PLC said Thursday its clinical study report on lung cancer drug VAL401 has been signed and approved by principal in ValiRx were

Read more
6 Sep 2018 09:05

ValiRx enters 'very exciting' phase for cancer therapies

(Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.